EBITDA Margin % is calculated as EBITDA divided by its Revenue. Can Fite Biopharma's EBITDA for the
six
months ended in Dec. 2025 was $-5.05 Mil. Can Fite Biopharma's Revenue for the
six
months ended in Dec. 2025 was $0.20 Mil. Therefore, Can Fite Biopharma's EBITDA margin for the quarter that ended in Dec. 2025 was -2,488.18%.
Can Fite Biopharma (AMEX:CANF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Can Fite Biopharma EBITDA Margin % Related Terms
Can Fite Biopharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Can Fite Biopharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CANF vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Can Fite Biopharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Can Fite Biopharma EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Can Fite Biopharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Can Fite Biopharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Can Fite Biopharma (CANF) has a EBITDA Margin % of -2,488.18% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Can Fite Biopharma and its competitors. According to the industry distribution chart, Can Fite Biopharma ranks #811 out of 945 companies in the Biotechnology industry, placing it in the top 85.8%.
Is Can Fite Biopharma's EBITDA Margin % too high?
Can Fite Biopharma's current EBITDA Margin % is -2,488.18%. Based on the distribution chart, Can Fite Biopharma ranks #811 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Can Fite Biopharma has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Can Fite Biopharma's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Can Fite Biopharma ranks #811 out of 945 companies for EBITDA Margin %. This places Can Fite Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Can Fite Biopharma and its competitors. Can Fite Biopharma's current EBITDA Margin % is -2,488.18%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Can Fite Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Can Fite Biopharma (CANF) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.98, compared to a current price of $2.99 — trading 50% below its estimated fair value. The current EBITDA Margin % is -2,488.18%. Can Fite Biopharma's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Can Fite Biopharma (CANF), the current EBITDA Margin % is -2,488.18% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Can Fite Biopharma (CANF) Overvalued in 2026?
Based on GuruFocus' analysis, Can Fite Biopharma stock appears to be undervalued.
The current stock price of $2.99 is trading 50% below its estimated GF Value™ of $5.98.
GuruFocus considers Can Fite Biopharma to be Significantly Overvalued.
Key valuation signals for CANF:
EBITDA Margin %: -2,488.18%
GF Value™: $5.98 vs. price of $2.99 (50% below fair value)
No single metric tells the full story. See the CANF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
55GF Score
Get the complete analysis for CANF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CANF has been successfully added to your 
